Technology

Curis

$10.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.69 (-6.30%) Today
+$0.38 (+3.70%) As of 1:03 PM UTC after-hours

Why Robinhood?

You can buy or sell Curis and other stocks, options, and ETFs commission-free!

About CRIS

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA. The listed name for CRIS is Curis, Inc. Common Stock.

CEO
James E. Dentzer
Employees
28
Headquarters
Lexington, Massachusetts
Founded
2000
Market Cap
914.20M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.59M
High Today
$11.17
Low Today
$10.11
Open Price
$10.96
Volume
2.11M
52 Week High
$13.44
52 Week Low
$0.62

Collections

CRIS Earnings

-$0.28
-$0.19
-$0.09
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 18, After Hours

You May Also Like

SHYD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure